CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans

Core Insights - CVS Health is expanding access to the weight loss drug Wegovy through its pharmacy benefit manager, Caremark, making it the preferred GLP-1 drug for obesity starting July 1 [2][3] - The partnership aims to enhance patient access to Wegovy, which is no longer in short supply in the U.S., and offers a lower net price compared to competitors [3][4] - Caremark will provide Wegovy at a more affordable price, with potential savings shared with clients through lower premiums or copays [4][5] Company Initiatives - Caremark will combine Wegovy with lifestyle support, including personalized nutrition plans, as part of the CVS Weight Management program [7] - CVS is the first retail pharmacy to partner with Novo Nordisk's direct-to-consumer online pharmacy, NovoCare, to dispense Wegovy at a lower price for cash-paying patients [6] - Novo Nordisk emphasizes the importance of collaborating with the healthcare system to provide affordable access to FDA-approved Wegovy [8]